In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone Cu-64-complexes for the positron emission tomography imaging of hypoxia

Department of Chemistry, Oxford University, Oxford, OX1 3TA, United Kingdom.
Journal of Medicinal Chemistry (Impact Factor: 5.48). 06/2008; 51(10):2985-91. DOI: 10.1021/jm800031x
Source: PubMed

ABSTRACT The copper(II) bisthiosemicarbazonato complex, copper-diacetyl-bis(N4-methylthiosemicarbazonate) (Cu-ATSM), has been used clinically as a positron emission tomography (PET) tracer for the delineation of hypoxia. Six novel, asymmetric bis(thiosemicarbazones) derived from diacetyl-2-(4-N-methyl-3-thiosemicarbazone)-3-(4-N-amino-3-thiosemicarbazone) (H2ATSM/A), one of which contained a nitroimidazole functionality, were radiolabeled with 64Cu (t1/2=12.7 h, beta+=19.3%). In vitro studies were performed on three of the compounds using EMT6 mammary carcinoma cells under hypoxic and normoxic conditions. All compounds displayed rapid cellular association and appreciable hypoxic selectivity with increased uptake under normoxic and hypoxic conditions when compared to 64Cu-ATSM. Biodistribution and small animal PET imaging studies were then carried out in vivo using two compounds in EMT6 tumor-bearing mice. The compounds showed high tumor uptake, but also substantial accumulation in the liver. These complexes demonstrate that H 2ATSM/A represents a novel and versatile synthetic platform that can be utilized to provide hypoxic cell selectivity through functionalization of the bisthiosemicarbazonate group.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: (64)Cu-diacetyl-bis(N(4)-methylthiosemicarbazonate), (64)Cu-ATSM, continues to be investigated clinically as a PET agent both for delineation of tumor hypoxia and as an effective indicator of patient prognosis, but there are still aspects of the mechanism of action that are not fully understood. The retention of radioactivity in tumors after administration of (64)Cu-ATSM in vivo is substantially higher for tumors with a significant hypoxic fraction. This hypoxia-dependent retention is believed to involve the reduction of Cu-ATSM, followed by the loss of copper to cellular copper processing. To shed light on a possible role of copper metabolism in hypoxia targeting, we have compared (64)Cu retention in vitro and in vivo in CaNT and EMT6 cells or cancers after the administration of (64)Cu-ATSM or (64)Cu-acetate. In vivo in mice bearing CaNT or EMT6 tumors, biodistributions and dynamic PET data are broadly similar for (64)Cu-ATSM and (64)Cu-acetate. Copper retention in tumors at 15 min is higher after injection of (64)Cu-acetate than (64)Cu-ATSM, but similar values result at 2 and 16 h for both. Colocalization with hypoxia as measured by EF5 immunohistochemistry is evident for both at 16 h after administration but not at 15 min or 2 h. Interestingly, at 2 h tumor retention for (64)Cu-acetate and (64)Cu-ATSM, although not colocalizing with hypoxia, is reduced by similar amounts by increased tumor oxygenation due to inhalation of increased O2. In vitro, substantially less uptake is observed for (64)Cu-acetate, although this uptake had some hypoxia selectivity. Although (64)Cu-ATSM is stable in mouse serum alone, there is rapid disappearance of intact complex from the blood in vivo and comparable amounts of serum bound activity for both (64)Cu-ATSM and (64)Cu-acetate. That in vivo, in the EMT6 and CaNT tumors studied, the distribution of radiocopper from (64)Cu-ATSM in tumors essentially mirrors that of (64)Cu-acetate suggests that copper metabolism may also play a role in the mechanism of selectivity of Cu-ATSM.
    Journal of Nuclear Medicine 12/2013; 55(1). DOI:10.2967/jnumed.113.119917 · 5.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The basic objective of this investigation is to explore potential metallo-organic antimicrobial agents based on metal-thiosemicarbazonates. This study acquires significance in the light of the antibacterial resistance exhibited by Gram-positive and Gram-negative bacterias which have become a serious global medical problem. The increasing drug resistant bacteria are responsible for various noscomial infections and among these, methicillin resistant Staphylococcus aureus (MRSA) is the most frequent noscomial pathogen. Likewise, Candida albicans (fungi) are found to have developed resistance against a number of antifungal agents. In this context, compounds of copper(II) with salicylaldehyde based thiosemicarbazones {5-R’-2-HO–C6H4-C2(H)=N3–N2H–C1(=S)–N1HR; R = H, Me, Et, Ph: H2L1, H2L2, H2L3, H2L4 respective thio-ligands] using bipyridines/phenanthrolines (L′) as co-ligands are being tested against various microorganisms (bacteria/fungi). For R’ = methoxy, several complexes (five coordinate complexes) were tested recently against gram positive bacteria such as Staphylococcus aureus (MTCC740), methicillin resistant Staphylococcus aureus (MRSA), gram negative bacteria, Shigella flexneri (MTCC1457), Klebsiella pneumoniae (MTCC109), P. aeruginosa (MTCC741) and yeast, Candida albicans (MTCC227). These complexes displayed significant growth inhibitory action even with low MIC (minimum inhibitory concenteration). A series of new copper(II) complexes (R′ = nitro, keeping R and co-ligands same) namely, [Cu(κ3-O,N,S-L)( κ2-N,N-L)] {(L)2- = (L1)2-, L= bipy, 1, phen, 2; (L)2- = (L2)2-, L= bipy, 3, phen, 4; (L)2- = (L3)2-, L= bipy, 5, phen, 6; (L)2- = (L4)2-, L= bipy, 7, phen, 8} have been isolated and characterized by elemental analysis, infrared and electronic absorption spectroscopy, ESR spectroscopy, fluorescence, single crystal x-ray crystallography. These copper(II) complexes have been investigated for their antimicrobial activity (antibacterial and antifungal activity), viable cell count studies through time kill assay and cellular toxicity testing using MTT assay against above mentioned bacteria/fungi. Several complexes have shown bactericidal effect with low cytotoxicity towards living cells (sheep blood used).
    RSC Advances 01/2015; 5(20). DOI:10.1039/C4RA15006F · 3.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel copper(II) complex with mixed ligands including β-[(3-formyl-5-methyl-2-hydroxy-benzylidene)amino]propionic acid anion and 1,10'-phenanthroline was synthesized, and its crystal structure was thoroughly characterized. It exerted excellent inducing apoptosis, anti-angiogenesis and antiproliferative properties in vitro. The complex can bind human serum albumin (HSA) at physiological pH conditions. Remarkably, it can induce formation of the mixed parallel/antiparallel G-quadruplex structures in the G-rich sequence of the proximal vascular endothelial growth factor (VEGF) promoter, and stabilize these G-quadruplex structures, which provide an opportunity for anti-angiogenesis chemotherapeutics. Furthermore, the complex showed a strong uptake, and exhibited multiple anticancer functions by inhibiting the expression of p-Akt and p-Erk1/2 proteins and by upregulating the levels of reactive oxygen species (ROS). Because of the reported results, this new copper(II) complex qualifies itself as a potential anticancer drug candidate.
    ChemMedChem 05/2014; DOI:10.1002/cmdc.201402060 · 3.05 Impact Factor


Available from
Jun 4, 2014